Le Lézard
Classified in: Health
Subjects: CCA, FVT

Endo Announces Second Quarter 2020 Earnings Call Time Change


DUBLIN, July 30, 2020 /CNW/ -- Endo International plc (NASDAQ: ENDP) today announced that it has changed the time of its previously announced conference call in an attempt to reduce conflicts with other earnings calls. The Company will now host a conference call and webcast on second-quarter 2020 financial results on August 6, 2020 at 7:00am EDT before the U.S. financial markets open. A press release with second-quarter 2020 financial results will be issued after the market closes on August 5, 2020.

The dial-in number to access the call is U.S./Canada (866) 497-0462, International (678) 509-7598, and the passcode is 2058864. Please dial in 10 minutes prior to the scheduled start time.

A replay of the call will be available from August 6, 2020 at 10:00 a.m. ET until 10:00 a.m. ET on August 13, 2020 by dialing U.S./Canada (855) 859-2056 International (404) 537-3406, and entering the passcode 2058864.

A simultaneous webcast of the call can be accessed by visiting http://investor.endo.com/events-and-presentations. In addition, a replay of the webcast will be available on the Company website for one year following the event.

About Endo International plc

Endo International plc (NASDAQ: ENDP) is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients in need through excellence in development, manufacturing and commercialization. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn more at www.endo.com.

SOURCE Endo International plc


These press releases may also interest you

at 01:05
KKR and Impilo Announce Strategic Partnership Together With Management in Rare Disease Platform Immedica Pharma
Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care...

at 01:01
Electroceuticals/Bioelectric Medicine Market to Reach $40.5 Billion, Globally, by 2032 at 7.4% CAGR: Allied Market Research
Allied Market Research published a report, titled, "Electroceuticals/Bioelectric Medicine Market by Product (Cardiac Pacemakers and Implantable Cardioverter Defibrillators, Cochlear Implants, Spinal Cord Stimulators, Deep Brain Stimulators, Vagus...

at 00:49
Inhaled Nitric Oxide Market to Reach $1.6 billion, Globally, by 2032 at 7.7% CAGR: Allied Market Research
Allied Market Research published a report, titled, "Inhaled Nitric Oxide Market by Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease, Acute Respiratory Distress Syndrome, and Others): Global Opportunity Analysis and...

at 00:45
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
Vertex Pharmaceuticals Incorporated and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-StemTM, to optimize production...

22 avr 2024
Diaphragm Pumps Market Projected to Reach $11.92 billion by 2030 - Exclusive Report by 360iResearch
The report titled "Diaphragm Pumps Market by Mechanism (Air-Operated, Electrical-Operated), Operation (Double Acting, Single Acting), Discharge Pressure, End-User - Global Forecast 2024-2030" is now available on 360iResearch.com's offering, presents...

22 avr 2024
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
ImmunityBio, Inc. , an immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of patients with...

More news about Health...


News published on and distributed by: